Remove 2020 Remove Compounding Remove FDA
article thumbnail

Opinion: Compounding pharmacies offer a fix for shortages of essential drugs

STAT

At the urging of the Alliance for Pharmacy Compounding, the trade association I lead, the Food and Drug Administration in April 2020 issued temporary guidance allowing traditional compounding pharmacies, within tight regulatory guardrails, to prepare 13 Covid drugs from pure ingredients to meet hospitals’ urgent need.

article thumbnail

7 health benefits of raspberry leaf tea

The Checkup by Singlecare

Red raspberry leaves are rich in tannins (a chemical compound) and flavonoids (a plant pigment), which both have antioxidant properties, according to research in Antioxidants journal. In a 2020 study , ellagic acid was shown to inhibit lung cancer cell proliferation and tumor growth. But what about the leaves?

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

DEA Reaffirms Synthetic THC Compounds Are Schedule I Controlled Substances

The FDA Law Blog

THC acetate esters are different than delta-9-THC, the psychoactive compound found naturally in the cannabis plant. Dr. Boos explained that delta-9-THCO and delta-8-THCO have similar chemical structures and pharmacological activities as compounds in the cannabis plant so they fall within the definition of THC. Terrence L. Boos, Ph.D.,

article thumbnail

Revised ISO guideline highlights toxicological evaluation of extractables and leachables

European Pharmaceutical Review

The guideline states that compounds “at or above the AET must be reported for toxicological risk assessment.” The researchers evaluated DHS extraction performance and compared it to traditional SHS and SBSE GC–MS methods. The paper highlighted that SHS analysis is currently a supplementary technique for volatile analysis.

article thumbnail

Clinical success begins early for small molecule drugs

European Pharmaceutical Review

Solving this before the clinical stage ensures the viability of compounds…” Addressing bioavailability challenges in the first phases of development is essential to help create the most robust product profile and increase the potential for success as small molecule drugs move to the clinic. amorphous solid dispersions, or ASDs.

article thumbnail

Ipsen beefs up in oncology, buying US biopharma Epizyme

pharmaphorum

Tazverik is a first-in-class EZH2a inhibitor that was cleared by the FDA in 2020 as a third-line or later treatment for adults with relapsed or refractory follicular lymphoma (FL) whose tumours have an EZH2 mutation. The post Ipsen beefs up in oncology, buying US biopharma Epizyme appeared first on.

article thumbnail

Can psychedelics provide breakthrough in mental health?

pharmaphorum

The term ‘psychedelic treatments’ incorporates a broad spectrum of different compounds, from LSD, psilocybin and DMT, to MDMA, ibogaine and ketamine. The latter compound has already been approved for treatment-resistance depression as the product Spravato (esketamine), after being developed by Janssen. Paving the way to patients.